Increased plasma asprosin levels in patients with drug-naive anorexia nervosa

Hu, Ying; Xu, Yixiang; Zheng, Yuchen; Kang, Qing; Lou, Zhongze; Liu, Qiang; Han, Chunchun; Ji, Yonghoon; Guo, Li; Chen, Chen; Ruan, Lifang; Chen, Jue

doi:10.1007/s40519-020-00845-3

Cited by 17 publications

(13 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the association of asprosin with adiposity is quite contradictory. For instance, individuals diagnosed with anorexia nervosa demonstrated elevated levels of asprosin [ 40 ]; while patients diagnosed with cancer-related anorexia had significantly lower levels of asprosin, positively correlating with body fat mass [ 41 ]. Moreover, a cohort study of 444 patients with PCOS and 156 controls found that circulating asprosin were independent of BMI in PCOS subjects [ 42 ].…”

Section: Discussionmentioning

confidence: 99%

Serum levels of Asprosin in patients diagnosed with coronary artery disease (CAD): a case-control study

et al. 2021

View full text Add to dashboard Cite

Background Coronary artery disease (CAD) is considered as a multi-faceted chronic inflammatory disease involving reduced blood supply to the myocardium as a result of accumulating lipids in the atrial walls. Visceral adiposity with disrupted release of adipokines play a key role in its pathogenesis. Asprosin is a newly identified fasting-induced glucogenic adipokine that has been related with metabolic disorders such as type II diabetes mellitus and polycystic ovary syndrome. The preset study sought to assess circulating asprosin in context of CAD. Methods In this study, serum levels of asprosin were determined in 88 CAD patients and 88 non-CAD healthy controls. Serum IL-6, TNF-α, asprosin and adiponectin were assessed using ELISA kits. Results: Serum asprosin was found to be higher in CAD patients when compared to non-CAD subjects (7.84 ± 2.08 versus 5.02 ± 1.29 μg/mL, p < 0.001). Similarly, serum TNF-α, and IL-6 elevated in CAD group significantly (p < 0.001). However, circulating adiponectin diminished in CAD group when compared with non-CAD subjects (p < 0.001). Moreover, serum asprosin levels directly correlated with BMI, FBG, HOMA-IR, TG and TC. Logistic regression analyses showed that asprosin levels were associated with increased risk of developing CAD (odds ratio: 3.01, 95% CI: 2.16, 4.20 and p < 0.001), after adjusting for potential confounders (age, sex and BMI). Conclusions The present study findings suggested a possible relation of serum asprosin with the pathogenesis of CAD, in particular through insulin resistance and dyslipidemia.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum levels of Asprosin in patients diagnosed with coronary artery disease (CAD): a case-control study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Administration of anti-asprosin antibodies significantly reduced pathologically elevated asprosin level and decreased AgRP neuron activity [ 9 ]. It should also be mentioned that researchers have shown that an increased level of asprosin may accompany anorexia nervosa and may be involved in the development of bulimia in these patients [ 18 ]. Other authors speculate that a decreased level of asprosin observed in oncological patients is either involved in the development of cancer anorexia or could be used to combat this condition [ 19 ].…”

Section: Asprosin and Appetitementioning

confidence: 99%

“…Olfr734 as an asprosin receptor [12] FBN1 gene mutation reduces asprosin production [7,9,10] Starvation induces asprosin production by white adipose tissue [7] Obesity state induces asprosin production by white adipose tissue [13] Mechanism of asprosin action via cAMP/PKC activation [7] Liver as a target organ for asprosin action-induction of glucose release [7,9] Appetite regulation Asprosin activates orexigenic agouti-related peptide (AgRP) neurons leading to appetite stimulation by the Gαs-cAMP-PKA axis [9] Anti-asprosin antibodies efficiently suppress AgRP neurons activation and food intake by insulin-resistant obese mice [9] Elevated asprosin level in diseases state in patients with obesity [20,21,35,36] in patients with insulin resistance [22,23] in patients with diabetes mellitus type 1 [24] in patients with diabetes mellitus type 2 [25][26][27] in patients with anorexia nervosa [18] in pregnant women with gestational diabetes mellitus [33] in pregnant women with pre-eclampsia [34] Decreased asprosin level in diseases state patients with neonatal progeroid syndrome (NPS) [7,8] [45] Physical activity in asprosin reduction 8-week aerobic exercise program reduces asprosin in mice with type 1 diabetes mellitus [48] Intermittent and continuous swimming training decrease asprosin levels in rats with metabolic syndrome [49] Acute aerobic exercise reduces asprosin level in healthy and obese men [50] Short-term high-intensive anaerobic exercise increases asprosin level in healthy women [12] Whole-body cryotherapy reduces asprosin level in menopausal women [52]…”

Section: Asprosin Actionmentioning

confidence: 99%

Asprosin—A Fasting-Induced, Glucogenic, and Orexigenic Adipokine as a New Promising Player. Will It Be a New Factor in the Treatment of Obesity, Diabetes, or Infertility? A Review of the Literature

Mazur-Biały

2021

Nutrients

View full text Add to dashboard Cite

Asprosin is a recently discovered protein released during fasting conditions mainly by adipocytes from white adipose tissue. As a glucogenic peptide, it stimulates the release of glucose from hepatic cells by binding to the OLFR734 receptor and leading to the activation of the G protein-cAMP-PKA pathway. As it crosses the blood–brain barrier, it also acts as an orexigenic peptide that stimulates food intake through activation of AgRP neurons in the hypothalamus; thus, asprosin participates in maintaining the body’s energy homeostasis. Moreover, studies have shown that asprosin levels are pathologically elevated in obesity and related diseases. However, the administration of anti-asprosin antibodies can both normalize its concentration and reduce food intake in obese mice, which makes it an interesting factor to combat obesity and related diseases. Current research also draws attention to the relationship between asprosin and fertility, especially in men. Asprosin improves age- and obesity-related decrease in fertility potential by improving sperm motility. It should also be mentioned that plasma asprosin levels can be differentially modulated by physical activity; intense anaerobic exercise increases asprosin level, while aerobic exercise decreases it. However, further research is necessary to confirm the exact mechanisms of asprosin activity and its potential as a therapeutic target.

show abstract

“…The authors of this work postulate that the abnormal interaction between asprosin and insula is the responsible link; insula plays an important role in some of the symptoms of AN. 22 …”

Section: Asprosin and Obesity Managementmentioning

confidence: 99%

A state of the art review on the novel mediator asprosin in the metabolic syndrome

Luís

Fernandes

Soares

et al. 2020

Porto Biomedical Journal

View full text Add to dashboard Cite

Metabolic syndrome is a complex and heterogeneous pathology characterized by a cluster of biochemical, clinical, and metabolic factors that came together in raising the risk of cardiovascular diseases, type 2 diabetes mellitus, and all-cause mortality. Some of these features are well defined in this syndrome like: obesity, inflammation, hypertension, insulin resistance, atherosclerotic dyslipidemias, endothelial dysfunction, and inflammation. This circuit is intermediated by a complex network of hormones, cytokines, transcription factors, and adipokines, among others. Some like leptin, adiponectin, Plasminogen activator inhibitor-1, interleukin-6, Tumor necrosis factor, and their influence on the metabolic syndrome are well described in the literature and new players are described continuously. One novel player was described in 2016 by Romere et al as a fasting-induced glycogenic protein hormone named asprosin. In order to perform a state-of-the-art, nonsystematic review of asprosin, a study of the available literature was carried out in the main database (Pubmed) and the results were studied and correlated to better understand the mechanism of action of this hormone. Asprosin is not only associated with the metabolic syndrome features like glucose and lipid metabolism, insulin resistance, obesity and inflammation but also in other pathologies metabolic syndrome related like diabetic retinopathy, polycystic ovary syndrome and anorexia nervosa. A limited number of pathways were already unveiled although much more research is needed to better understand the therapeutical potential of asprosin in the metabolic syndrome.

show abstract

Increased plasma asprosin levels in patients with drug-naive anorexia nervosa

Cited by 17 publications

References 70 publications

Serum levels of Asprosin in patients diagnosed with coronary artery disease (CAD): a case-control study

Serum levels of Asprosin in patients diagnosed with coronary artery disease (CAD): a case-control study

Asprosin—A Fasting-Induced, Glucogenic, and Orexigenic Adipokine as a New Promising Player. Will It Be a New Factor in the Treatment of Obesity, Diabetes, or Infertility? A Review of the Literature

A state of the art review on the novel mediator asprosin in the metabolic syndrome

Contact Info

Product

Resources

About